Co-Authors
This is a "connection" page, showing publications co-authored by Carlomaurizio Montecucco and Sara Monti.
Connection Strength
11.923
-
Fast-Track Ultrasound Clinic for the Diagnosis of Giant Cell Arteritis Changes the Prognosis of the Disease but Not the Risk of Future Relapse. Front Med (Lausanne). 2020; 7:589794.
Score: 0.917
-
Response to: 'Increased rather than decreased incidence of giant-cell arteritis during the COVID-19 pandemic' by Lecler et al. Ann Rheum Dis. 2020 Sep 22.
Score: 0.904
-
Response to: 'Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops et al. Ann Rheum Dis. 2021 05; 80(5):e68.
Score: 0.889
-
Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak. Ann Rheum Dis. 2020 Jun 05.
Score: 0.886
-
Impact of delayed diagnoses at the time of COVID-19: increased rate of preventable bilateral blindness in giant cell arteritis. Ann Rheum Dis. 2020 12; 79(12):1658-1659.
Score: 0.884
-
Comorbidities and rheumatological diseases at the time of COVID-19. Response to: 'Rheumatic diseases in intensive care unit patients with COVID-19' by Moiseev et al. Ann Rheum Dis. 2021 02; 80(2):e17.
Score: 0.883
-
Prevalence of COVID-19 among patients with rheumatic diseases: the need to await results from large collaborative studies. Response to: 'COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs' by Conticini et al. Ann Rheum Dis. 2021 02; 80(2):e15.
Score: 0.882
-
Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: 'Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: lessons from a case with severe pneumonia' by Guilpain et al. Ann Rheum Dis. 2021 01; 80(1):e11.
Score: 0.880
-
Non-steroidal anti-inflammatory treatment during covid-19: friend or foe? Response to: 'Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)' by Giollo et al. Ann Rheum Dis. 2021 02; 80(2):e13.
Score: 0.880
-
The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al. Ann Rheum Dis. 2021 01; 80(1):e3.
Score: 0.879
-
Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit. Ann Rheum Dis. 2020 06; 79(6):e62.
Score: 0.878
-
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020 05; 79(5):667-668.
Score: 0.875
-
Correspondence on 'EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs'. Ann Rheum Dis. 2021 10; 80(10):e156.
Score: 0.236
-
Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data? Arthritis Rheumatol. 2020 10; 72(10):1600-1606.
Score: 0.225
-
Early development of new cardiovascular risk factors in the systemic vasculitides. Clin Exp Rheumatol. 2020 Mar-Apr; 38 Suppl 124(2):126-134.
Score: 0.210
-
20 years of experience with tumour necrosis factor inhibitors: what have we learned? Rheumatology (Oxford). 2018 10 01; 57(57 Suppl 7):vii5-vii10.
Score: 0.197
-
Clinical spectrum of anti-Jo-1-associated disease. Curr Opin Rheumatol. 2017 Nov; 29(6):612-617.
Score: 0.185
-
Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors. Mod Rheumatol. 2018 May; 28(3):542-549.
Score: 0.183
-
IgG4-related diseases: state of the art on clinical practice guidelines. RMD Open. 2018; 4(Suppl 1):e000787.
Score: 0.050